Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Selinexor and Docetaxel in Treating Participants with Stage IV KRAS Mutant Non-Small Cell Lung Cancer

Multiple Cancer Types

This phase I / II trial studies the safety and best dose of selinexor and docetaxel in treating participants with stage IV KRAS-mutation non-small cell lung cancer that has spread to other places in the body. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving selinexor and docetaxel may work better in treating participant with stage IV KRAS mutant non-small cell lung cancer.
Lung, Non Small Cell
I/II
Horn, Leora
NCT03095612
VICCTHO1791

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: